» Articles » PMID: 33376411

In-vitro Evaluations of Quality Control Parameters of Paracetamol Tablets Marketed in Gondar City, Northwest Ethiopia

Overview
Publisher Dove Medical Press
Specialty Health Services
Date 2020 Dec 30
PMID 33376411
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The aim of this research was to evaluate quality control parameters of available brands of paracetamol tablets in Gondar city since standard quality parameters are essential for a better quality of the product. The different brands of paracetamol tablets were obtained from local pharmacies in Gondar town and the University of Gondar (UOG) hospital pharmacies.

Methods: Five brands of paracetamol, from each, 102 tablets were collected from private pharmacies, government health centers, and UOG pharmacies. The popular brands in the city, Panadol, Para-denk, Paramol, Paracetamol (EPHARM), and Cadimol, conventional tablets of 500 mg strength were chosen and the tablets were assessed for different quality parameters: weight variation, hardness, friability, disintegration, dissolution, and drug content (assay) using compendial methods. The tablets were evaluated to check if they comply with the specifications of USP (United States Pharmacopeia).

Results: From the results, it was observed that all the brands of paracetamol have passed the tests and met the specifications of USP. Results of weight variation, hardness, friability, and disintegration time ranged from 0.46 to 1.11%, 117.0 to 174.70 N, 0.07 to 0.63%, and 01 to 08 minutes for all the tablets, respectively. The dissolution profiles of all the brands are within the acceptable label claim. The assay results showed that the drug content of the paracetamol brands ranged from 95.04% to 106.81%. The dissolution rate was significantly different (p < 0.05) as compared to code 1 with all brands tested at 30 minutes. The disintegration time of different brands was also significantly different from the comparator (code 1) except code 2.

Conclusion: Based on the finding from this study, there were no significant deviations from pharmacopeia standards and specifications. The brands studied were safe enough and could be used to achieve the desired therapeutic effect.

Citing Articles

Formulation, Quality Control and Stability Study of Pediatric Oral Dextrose Gel.

Lamy E, Orneto C, Ali O, Kireche L, Mathias F, Bouguergour C Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40006018 PMC: 11858957. DOI: 10.3390/ph18020204.


Cost-effective track and trace technology for poor-quality chemotherapeutic pharmaceuticals in resource-limited countries: a review of the Chemotherapeutic Paper Analytical Device.

Worku M, Limenh L, Mekonnen B, Anagaw Y Front Med Technol. 2024; 6:1436614.

PMID: 39640069 PMC: 11617187. DOI: 10.3389/fmedt.2024.1436614.


Post-marketing quality surveillance of selected antibacterial agents marketed in porous borders; the case of Ethiopia-Sudan-Eritrea border.

Denekew T, Eticha T, Teshome Y, Endeshaw S, Ashenef A PLoS One. 2024; 19(8):e0308223.

PMID: 39133679 PMC: 11318851. DOI: 10.1371/journal.pone.0308223.


Quality of veterinary anthelmintic drugs marketed in Gondar Zones, North West Ethiopia; presence of poor-quality medicines.

Getahun M, Tefera B, Bacha B, Eticha T, Ashenef A Heliyon. 2023; 9(7):e18023.

PMID: 37483800 PMC: 10362142. DOI: 10.1016/j.heliyon.2023.e18023.

References
1.
Zaid A, Rinno T, Jaradat N, Jodeh S, Khammash S . Interchangeability between paracetamol tablets marketed in Palestine. Is there a quality reason for a higher price?. East Mediterr Health J. 2014; 19(6):542-6. View

2.
Nsimba S . Problems associated with substandard and counterfeit drugs in developing countries: a review article on global implications of counterfeit drugs in the era of antiretroviral (ARVs) drugs in a free market economy. East Afr J Public Health. 2009; 5(3):205-10. DOI: 10.4314/eajph.v5i3.39004. View

3.
Okumura J, Wakai S, Umenai T . Drug utilisation and self-medication in rural communities in Vietnam. Soc Sci Med. 2002; 54(12):1875-86. DOI: 10.1016/s0277-9536(01)00155-1. View

4.
Attaran A, Barry D, Basheer S, Bate R, Benton D, Chauvin J . How to achieve international action on falsified and substandard medicines. BMJ. 2012; 345:e7381. DOI: 10.1136/bmj.e7381. View

5.
Ozawa S, Evans D, Bessias S, Haynie D, Yemeke T, Laing S . Prevalence and Estimated Economic Burden of Substandard and Falsified Medicines in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis. JAMA Netw Open. 2019; 1(4):e181662. PMC: 6324280. DOI: 10.1001/jamanetworkopen.2018.1662. View